| Umsatz in Mio. | - |
| Operatives Ergebnis (EBIT) in Mio. | -103,20 $ |
| Jahresüberschuss in Mio. | -95,88 $ |
| Umsatz je Aktie | - |
| Gewinn je Aktie | -0,48 $ |
| Gewinnrendite | -55,92% |
| Umsatzrendite | - |
| Return on Investment | -45,04% |
| Marktkapitalisierung in Mio. | 608,45 $ |
| KGV (Kurs/Gewinn) | -6,40 |
| KBV (Kurs/Buchwert) | 3,53 |
| KUV (Kurs/Umsatz) | - |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +80,54% |
| Geld/Brief | 5,50 € / 5,65 € |
| Spread | +2,73% |
| Schluss Vortag | 5,575 € |
| Gehandelte Stücke | 0 |
| Tagesvolumen Vortag | - |
| Tagestief 5,575 € Tageshoch 5,575 € | |
| 52W-Tief 1,535 € 52W-Hoch 5,675 € | |
| Jahrestief 1,535 € Jahreshoch 5,675 € | |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 5,55 € | +3,74% | 5,35 € | 05.12.25 | |
| Frankfurt | 5,55 € | +3,74% | 5,35 € | 05.12.25 | |
| München | 5,40 € | +1,89% | 5,30 € | 05.12.25 | |
| Stuttgart | 5,55 € | +3,74% | 5,35 € | 05.12.25 | |
| L&S RT | 5,575 € | 0 % | 5,575 € | 11:47 | |
| Berlin | 5,40 € | +0,93% | 5,35 € | 05.12.25 | |
| NYSE | 6,505 $ | +2,04% | 6,375 $ | 05.12.25 | |
| Nasdaq | 6,505 $ | +2,12% | 6,37 $ | 05.12.25 | |
| AMEX | 6,50 $ | +2,85% | 6,32 $ | 05.12.25 | |
| Tradegate | 5,55 € | +0,91% | 5,50 € | 05.12.25 | |
| Quotrix | 5,50 € | +0,92% | 5,45 € | 05.12.25 | |
| Gettex | 5,65 € | +3,67% | 5,45 € | 05.12.25 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 05.12.25 | 5,575 | - |
| 04.12.25 | 5,475 | - |
| 03.12.25 | 5,40 | - |
| 02.12.25 | 5,125 | - |
| 01.12.25 | 5,065 | - |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 5,375 € | +3,72% |
| 1 Monat | 3,46 € | +61,13% |
| 6 Monate | 2,18 € | +155,73% |
| 1 Jahr | 3,53 € | +57,93% |
| 5 Jahre | 1,18 € | +372,46% |
| Marktkapitalisierung | 500,77 Mio. € |
| Aktienanzahl | 135,34 Mio. |
| Streubesitz | 6,50% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +14,16% | NEA Management Company, LLC |
| +10,18% | Bain Capital Life Sciences Investors, LLC |
| +7,15% | TCG Crossover Management, LLC |
| +6,37% | Vestal Point Capital LP |
| +5,66% | BlackRock Inc |
| +5,14% | VR Adviser, LLC |
| +4,89% | Vanguard Group Inc |
| +4,82% | Nantahala Capital Management, LLC |
| +4,61% | Deerfield Management Co |
| +3,95% | Farallon Capital Management, L.L.C. |
| +2,08% | ADAR1 Capital Management LLC |
| +2,04% | Emerald Advisers, LLC |
| +1,94% | Wellington Management Company LLP |
| +1,72% | Geode Capital Management, LLC |
| +1,54% | Rosalind Advisors, Inc. |
| +1,42% | Sofinnova Ventures |
| +1,42% | State Street Corp |
| +1,26% | Emerald Mutual Fund Advisers Trust |
| +0,76% | Sphera Funds Management Ltd. |
| +0,65% | SUPERSTRING CAPITAL MANAGEMENT LP |
| +11,73% | Weitere |
| +6,50% | Streubesitz |
Zahlen für Q1/24
- Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024
- the Company Continues to Believe it is Sufficiently Capitalized into 2026
https://savarapharma.com/investors/press-releases/release/?id=14706